- Home
- RCUS vs HQH Comparison
RCUS vs HQH Comparison
Compare RCUS & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- HQH
- Stock Information
- Founded
- RCUS 2015
- HQH 1986
- Country
- RCUS United States
- HQH United States
- Employees
- RCUS N/A
- HQH N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- HQH Finance Companies
- Sector
- RCUS Health Care
- HQH Finance
- Exchange
- RCUS Nasdaq
- HQH Nasdaq
- Market Cap
- RCUS 906.4M
- HQH 826.8M
- IPO Year
- RCUS 2018
- HQH N/A
- Fundamental
- Price
- RCUS $8.54
- HQH $15.73
- Analyst Decision
- RCUS Buy
- HQH
- Analyst Count
- RCUS 10
- HQH 0
- Target Price
- RCUS $23.75
- HQH N/A
- AVG Volume (30 Days)
- RCUS 1.2M
- HQH 183.8K
- Earning Date
- RCUS 08-07-2025
- HQH 01-01-0001
- Dividend Yield
- RCUS N/A
- HQH 11.56%
- EPS Growth
- RCUS N/A
- HQH N/A
- EPS
- RCUS N/A
- HQH 1.09
- Revenue
- RCUS $141,000,000.00
- HQH N/A
- Revenue This Year
- RCUS N/A
- HQH N/A
- Revenue Next Year
- RCUS $28.73
- HQH N/A
- P/E Ratio
- RCUS N/A
- HQH $15.24
- Revenue Growth
- RCUS N/A
- HQH N/A
- 52 Week Low
- RCUS $6.50
- HQH $14.31
- 52 Week High
- RCUS $18.98
- HQH $17.94
- Technical
- Relative Strength Index (RSI)
- RCUS 46.40
- HQH 55.01
- Support Level
- RCUS $7.92
- HQH $15.41
- Resistance Level
- RCUS $8.61
- HQH $15.89
- Average True Range (ATR)
- RCUS 0.45
- HQH 0.24
- MACD
- RCUS -0.09
- HQH 0.03
- Stochastic Oscillator
- RCUS 40.00
- HQH 76.19
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.